Organon (OGN) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 30.1% versus a loss of 7.0%. Over five years, XENE leads with a +8.2% price change compared with -60.5% for OGN. Organon is the larger company by market cap ($3.62 billion vs $3.44 billion), about 1.1 times the size.
Organon pays a dividend yielding 0.58%, while Xenon Pharmaceuticals does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGN | XENE |
|---|---|---|
| Share price | $13.79 | $35.52 |
| Market cap | $3.62B | $3.44B |
| 1-day change | -0.04% | -2.46% |
| YTD return | +92.33% | -18.76% |
| 1-year return | +30.09% | -7.02% |
| 5-year return | -60.48% | +8.17% |
| P/E ratio (TTM) | 17.67 | — |
| Forward P/E | 3.81 | — |
| EPS (TTM) | $0.78 | $-4.74 |
| Dividend yield | 0.58% | 0.00% |
| Annual dividend | $0.08 | $0.00 |
| Revenue (latest FY) | $6.22B | $7.50M |
| Revenue growth (YoY) | -2.92% | — |
| Net income (latest FY) | $187.00M | $-345.91M |
| Gross margin | 53.30% | — |
| Operating margin | — | -4974.27% |
| Net margin | 3.01% | -4612.13% |
| 52-week high | $13.79 | $72.66 |
| 52-week low | $5.69 | $35.50 |
| Distance from 52-week high | -0.04% | -51.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -18.39% | +106.59% |
| Average volume | 2.64M | 1.43M |
| Shares outstanding | 262.61M | 96.84M |
| Employees | 10,000 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed XENE by 37.1 percentage points over the past year.
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
OGN vs XENE FAQ
Which is bigger, Organon or Xenon Pharmaceuticals?
Organon (OGN) is larger, with a market capitalization of $3.62B compared with $3.44B for Xenon Pharmaceuticals (XENE).
Which stock has performed better over the past year, OGN or XENE?
OGN returned +30.09% over the past 12 months, compared with -7.02% for XENE (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Organon or Xenon Pharmaceuticals?
Organon pays a dividend yielding 0.58%, while Xenon Pharmaceuticals does not currently pay a regular dividend.
Are Organon and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.